Athena Athena

X
[{"orgOrder":0,"company":"Biocad","sponsor":"Shanghai Pharmaceuticals Holding Co.,Ltd","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Clinical Trial of An Original Russian Drug for The Treatment of Lung Cancer Starts in China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"RUSSIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Biocad"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The BIOCAD and Shanghai Pharmaceuticals Holding joint venture has announced enrollment of patient with treatment prolgolimab in BCD-100-3/DOMAJOR clinical trial of an original anti-PD1 check point inhibitor in patients with non-small cell lung cancer (NSCLC) by BIOCAD.

            Lead Product(s): BCD-100,Pemetrexed,Cisplatin

            Therapeutic Area: Oncology Product Name: BCD-100

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Shanghai Pharmaceuticals Holding Co.,Ltd

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 13, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY